论文部分内容阅读
目的:肝纤维化程度及自身抗体表达对熊去氧胆酸单药治疗自身免疫性肝病重叠综合征患者临床疗效的影响。方法:回顾性收集2007年-2011年住院的20例做过肝穿活检的经熊去氧胆酸单药治疗达到满意效果的自身免疫性肝炎和原发性胆汁性肝硬化重叠综合征患者的临床资料。结果:20例患者中,12例患者(60%)的肝穿标本活检评估处于肝纤维化S3或S4期,其初诊时基线特征与肝纤维化处于S0-S2期的患者基线特征无统计学差异。此外,该20例患者的血清抗平滑肌抗体的阳性率较低(1/20)。结论:肝脏纤维化程度不会引起熊去氧胆酸治疗效果的下降。
Objective: To investigate the effect of autoantibodies and liver fibrosis on the clinical efficacy of ursodeoxycholic acid monotherapy in patients with autoimmune liver disease overlap syndrome. METHODS: Twenty patients admitted to our hospital between 2007 and 2011 with satisfactory results were enrolled in this study. Twenty patients who had been admitted to our hospital with biopsy of liver biopsy were retrospectively collected for the treatment of patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome clinical information. RESULTS: Twelve patients (60%) of the 20 patients were biopsied for liver biopsy in stages S3 or S4 of liver fibrosis with no statistical difference in baseline characteristics at baseline or in patients with liver fibrosis at stage S0-S2 difference. In addition, the 20 patients had a lower positive rate of anti-smooth muscle antibodies (1/20). Conclusions: The degree of liver fibrosis does not cause a decrease in the effect of ursodeoxycholic acid.